Pmh40 - Cost-Minimisation Analysis of Second Generation Long Acting Injectables (Risperidone , Paliperidone, and Aripiprazole) for Schizophrenia in Spanish Medium-Long Term Care Psychiatric Units

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1675
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Treatment Cost Comparison: Paliperidone Palmitate Versus Risperidone Long Acting in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost Effectiveness of Paliperidone Palmitate Versus Risperidone Long-Acting Injectable, Quetiapine and Olanzapine for the Treatment of Patients With Schizophrenia in Colombia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Quality of Life of Patients Suffering From Schizophrenia and Treated With Long-Acting Risperidone and Paliperidone-Palmitate

Racionalna terapija
2018English

Caregiver Burden in Schizophrenia Following Paliperidone Palmitate Long Acting Injectables Treatment: Pooled Analysis of Two Double-Blind Randomized Phase Three Studies

npj Schizophrenia
PsychiatryMental Health
2017English

Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia

Psychiatric Services
MedicinePsychiatryMental Health
2016English

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”

Case Reports in Psychiatry
PsychiatryMental Health
2019English

Pmh25 - Early Administration of Aripiprazole Long-Acting Injectable in Acute Inpatients With Schizophrenia Reduces the Cost of Hospitalization

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Treatment Discontinuation of Long-Acting Injectables or Oral Atypical Antipsychotics Among Medicaid Recipients With Schizophrenia

Journal of Medical Economics
Health Policy
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy